Navigation Links
Sanofi and Regeneron Launch Comprehensive Phase 3 Clinical Program With LDL Cholesterol-Lowering PCSK9 Antibody
Date:7/19/2012

nical trials designed to test the efficacy and long-term safety of SAR236553/REGN727 both as monotherapy, and in combination with other lipid-lowering agents.  ODYSSEY will enroll several patient populations including patients with heFH who are inadequately controlled by current lipid-modifying therapy, and high cardiovascular risk patients with primary hypercholesterolemia.  The primary efficacy parameter will be LDL-C; however, multiple lipid parameters will be evaluated.  The global Phase 3 program will be conducted across more than 2,000 study centers across the United States, Canada, Western and Eastern Europe, South America, Australia and Asia.  The Phase 3 ODYSSEY program will include the following studies:

  • ODYSSEY FH I, FH II and HIGH FH: The primary objective of these three studies is to demonstrate the efficacy and safety of SAR236553/REGN727 as an add-on therapy in patients with heFH who are not adequately controlled with their lipid-modifying therapy.
  • ODYSSEY COMBO I and COMBO II: The primary objective of these two studies is to demonstrate the safety and efficacy of SAR236553/REGN727 as an add-on therapy in patients with primary hypercholesterolemia at high cardiovascular risk who are not adequately controlled with their lipid-modifying therapy.
  • ODYSSEY MONO: The primary objective of this study is to demonstrate the safety and efficacy of SAR236553/REGN727 as monotherapy in comparison with ezetimibe in patients with primary hypercholesterolemia.
  • ODYSSEY ALTERNATIVE: The primary objective of this study is to demonstrate the safety and efficacy of SAR236553/REGN727 in comparison with ezetimibe in patients with primary hypercholesterolemia (heFH and non-familial hypercholesterolemia) who are unable to tolerate statins.
  • ODYSSEY OPTIONS I and OPTIONS II: The primary objective of these studies is to evaluate the safety and efficacy of SAR236553/REGN727 as an add
    '/>"/>

SOURCE Sanofi and Regeneron Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Sanofi Signs Agreement for Type 1 Diabetes Research with Boston Academic Teaching Hospital
2. Collaboration between Sanofi and Joslin Diabetes Center to focus on new drugs for diabetes
3. Sanofi and Regeneron Announce Publication of Positive Phase 2 Results for Lipid-Lowering PCSK9 Antibody in The Lancet
4. Former Sanofi-aventis and US Oncology Executive Joins New Century Health as Chief Executive Officer
5. PharmaVentures Client Sanofi Wins Scrip Outsourcing Deal of the Year Award
6. Regeneron Announces March 2012 Investor Conference Presentations
7. Regeneron Announces Presentation at the Leerink Swann 2012 Global Healthcare Conference
8. Elsevier Launches International Journal for Parasitology: Parasites and Wildlife
9. Elsevier Launches a New Product Literature Database Solution for Life Science Professionals
10. GenoSpace Announces the Launch of a Cloud-Based "Information Ecosystem" for Advancing 21st-Century Personalized Medicine
11. infirst HEALTHCARE Established to Launch Novel Consumer Medicines
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... (HZDR), the Vienna University of Technology and the ... nearly perfect semiconductor crystals into a silicon nanowire. ... very fast and multi-functional processing units can be ... The research results will be published in the ... considered the cornerstone of future chip technology, but ...
(Date:7/23/2014)... Last year, Formedix celebrated its partnership ... of data management solutions for clinical trials. The company ... electronic data capture (EDC) and clinical data management. Formedix, ... tools added TrialMaster to its Transform for EDC product ... for TrialMaster, is being released this week, in response ...
(Date:7/23/2014)... July 23, 2014 ... of Trendlines Agtech , announced it has ... Israel,s leading agricultural thermoplastics applications companies. ... Valentis,s technology combines nanocrystalline cellulose (NCC), a biodegradable, ... additional nanoparticles to produce highly improved polymeric films. ...
(Date:7/23/2014)... July 23, 2014 Shire ... the global specialty biopharmaceutical company, and ArmaGen, a ... worldwide licensing and collaboration agreement for AGT-182, an ... treatment of both the central nervous system (CNS) ... (MPS II). This collaboration strengthens Shire,s rare disease ...
Breaking Biology Technology:A crystal wedding in the nanocosmos 2Formedix and OmniComm Systems® Partnership Strengthened with the Release of Enhanced TrialMaster® Integration for EDC Build 2Formedix and OmniComm Systems® Partnership Strengthened with the Release of Enhanced TrialMaster® Integration for EDC Build 3Valentis Nanotech Signs MOU to Integrate Technology in Thermoplastics Production 2Shire Enters Strategic Licensing and Collaboration Agreement With ArmaGen 2Shire Enters Strategic Licensing and Collaboration Agreement With ArmaGen 3Shire Enters Strategic Licensing and Collaboration Agreement With ArmaGen 4Shire Enters Strategic Licensing and Collaboration Agreement With ArmaGen 5
... Harry Whelan has become the first Medical College ... Defense University in Washington, D.C. , ,Whelan, a professor of ... signed a two-year contract at the Center for Technology ... around the country receiving the appointment, he will be spending ...
... Institute predicts moderate Wisconsin biopharmaceutical growth ... Third Wave appoints regulatory director , ... ,Wisconsin is home to significant biopharmaceutical innovation but ... a recent report prepared by the Milken ...
... group of Midwest technology consultants and you want to get them talking, ... free? Its an amazing thing. , ,You can ply your trade inside ... and all you have to do is hang out a shingle. All ... you to perform your services for no money. , ,When I used ...
Cached Biology Technology:Medical College of Wisconsin researcher gets national defense appointment 2Tech Digest: whats moving in the Midwest 2Dont work for free on a maybe someday 2Dont work for free on a maybe someday 3Dont work for free on a maybe someday 4
(Date:7/23/2014)... is available in German . ... to cells, drive metabolic processes and transmit signals. To ... shapes. Scientists at the Max Planck Institute for Developmental ... be constructed of similar amino acid chains even when ... proteins that exist today arose from common precursors. Presumably, ...
(Date:7/23/2014)... BioCatch, the global leader in cognitive biometric ... named in Gartner,s Market Guide for Online Fraud Detection ... Quadrant for Web Fraud Detection. In the ... to deliver passive biometric analysis and predicted, "By 2017, ... at least 30% of one-stop fraud detection solutions - ...
(Date:7/23/2014)... for clinical use of induced pluripotent stem cell ... been hindered by the risk of dysregulated cell ... to use etoposide treatment to halt teratoma formation ... specifically acute myocardial infarction, is demonstrated in an ... a peer-reviewed journal from Mary Ann Liebert, Inc., ...
Breaking Biology News(10 mins):Protein evolution follows a modular principle 2BioCatch Featured in Gartner's 2014 Online Fraud Detection Market Guide 2BioCatch Featured in Gartner's 2014 Online Fraud Detection Market Guide 3
... latest-generation DNA sequencing technology to become the first explorers ... "This project is one of the first attempts to ... than a single organism," says Nicole Gerardo, assistant professor ... we can understand how these ants have evolved to ...
... the Centers for Disease Control and Prevention (CDC) found ... by age of menarche and total number of lifetime ... over the course of a woman,s lifetime may influence ... this study are published in Cancer Epidemiology, Biomarkers ...
... We see the face of the Virgin Mary staring up ... portion of our meal for $37,000 on eBay. We believe in ... science offers a wealth of rational explanations for natural phenomena, we ... And we,ll even go to war to protect our delusions against ...
Cached Biology News:Landmark project to map genomics of complex ant systems 22 reproductive factors are important predictors of death from ovarian cancer 22 reproductive factors are important predictors of death from ovarian cancer 3Our 'caveman logic' embraces ESP over evolution 2
Umbilical cord blood CD4+ T cells, For immunohistochemistry (IHC) Cell Chip with Human Umbilical Cord Blood MNCs and T Cells...
Human endothelial progenitor cells, For immunohistochemistry (IHC) Cell Chip with Human Peripheral Blood Dendritic Cells and EPCs...
Human monocyte-derived dendritic cells, For immunohistochemistry (IHC) Cell Chip with Human Peripheral Blood Dendritic Cells and EPCs...
...
Biology Products: